How much funding has Allogene Therapeutics raised?

Allogene Therapeutics has raised $420.0M in total funding, most recently a Series B round.

Who are Allogene Therapeutics's investors?

Allogene Therapeutics's investors include Perceptive Advisors, Pfizer Ventures, TPG (Growth/Rise), Two River Group, Deerfield Management, Fidelity Management.

When was Allogene Therapeutics founded?

Allogene Therapeutics was founded in 2018.

Where is Allogene Therapeutics headquartered?

Allogene Therapeutics is headquartered in South San Francisco, California, United States.

What industry is Allogene Therapeutics in?

Allogene Therapeutics operates in Biotech, Healthcare.

How many employees does Allogene Therapeutics have?

Allogene Therapeutics has 51-200 employees.

Allogene Therapeutics

IPO

Home - Allogene

Public · South San Francisco, United States · Founded 2018 · $420.0M raised

Biotech

Healthcare

Headquarters: South San Francisco, California
Employees: 51–200
Founded: 2018
Business Model: B2B
Website: allogene.com

Total Funding: $420.0M
Last Round: $120.0M Series BApr 2018
Rounds: 2
Type: Public

About

Allogene Therapeutics is a clinical-stage biotech pioneering allogeneic CAR T cell therapies — off-the-shelf treatments derived from healthy donor cells — targeting blood cancers and autoimmune diseases. Its pipeline includes ALLO-329 (dual-targeting, FDA IND-cleared 2025) and multiple earlier-generation ALLO-series candidates. The company went public in 2018.

Summary

Allogene Therapeutics is a Biotech company based in South San Francisco, United States, founded in 2018. It has raised $420.0M in total across 2 rounds, most recently a $120.0M Series B round in Apr 2018. Investors include Perceptive Advisors, Pfizer Ventures and TPG (Growth/Rise).

LinkedIn X (Twitter)